Clinical Trial Update: Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating de-escalation from natalizumab to interferon-beta-1b in relapsing-remitting multiple sclerosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Betaseron (Interferon beta-1b)
• Extavia (interferon beta-1b)
• Tysabri (Natalizumab)

Snippet

Sponsor: Claudio Gobbi | Conditions: Relapsing-remitting Multiple Sclerosis | Phase 4 | Status: TERMINATED